Senior Medical Director, Treatment - Global Medical Affairs, ViiV

ViiV Healthcare•Durham, NC

About The Position

Provide senior global medical leadership for the long-acting HIV portfolio, with primary accountability for an emerging treatment programme and its evidence, communication and launch-readiness agenda. Establish the global medical and scientific strategic direction, short- and long-term goals, and the overall planning and delivery of integrated medical affairs plans for the next-generation long-acting treatment portfolio. Work in close partnership with the broader long-acting franchise to ensure a coherent, joined-up medical strategy across the portfolio. Collaborate across current and future long-acting and combination assets to maximise the collective value of the franchise and support a seamless scientific narrative across treatment and prevention. Build and develop a global medical capability to support the evolving portfolio, with responsibility for leading and developing a team of up to four professionals over time. Operate effectively within a complex, highly matrixed environment, navigating uncertainty and shaping strategy as the scientific, competitive and policy landscapes evolve. Ensure ViiV Healthcare’s scientific and medical data are leveraged effectively and communicated in a fair, balanced and compliant manner in line with ABPI/PMCPA and other applicable codes. Partner across Clinical, Statistics, Regulatory, Safety, Commercial, Market Access, Policy, Scientific Communications and Compliance to shape the pipeline evidence strategy and support responsible commercialisation.

Requirements

MD, PharmD or PhD in a medical / scientific discipline or public health
Experience of working in the HIV or infectious disease therapy area
Proven experience leading global medical strategy and integrated evidence plans across pre- and post-launch phases.
Track record of interfacing with Commercial, Regulatory, Statistics, Scientific Communications and R&D in a matrix organisation.
Experience leading an asset or indication within medical affairs in a local affiliate (in country) role
Experience leading and developing people and teams, including indirect / matrix leadership

Nice To Haves

ABPI (or equivalent) Code reviewer / nominated Final Medical Signatory experience.
Experience in launch excellence, scientific platform development and evidence review.
Experience of resistance, pharmacology and service-delivery / implementation science for long-acting therapies.
Demonstrated ability to influence senior internal and external stakeholders and shape policy / market environments.

Responsibilities

Set and own the integrated global medical strategy and integrated evidence plan for the emerging pipeline treatment, spanning pre-launch to post-launch phases.
Work in partnership with the established long-acting treatment team to create an aligned medical strategy, integrated evidence plan and coherent scientific narrative across the treatment portfolio.
Build, develop and lead a high-performing global medical capability to support the long-acting treatment pipeline, with responsibility for up to four direct reports as the organisation and portfolio evolve. Demonstrate strong collaborative leadership, build alignment across functions, and deliver effectively amid ambiguity, changing priorities and emerging evidence.
Work directly with other long-acting franchise leads to ensure a joined-up franchise medical strategy and consistent external scientific positioning.
Shape and oversee the pipeline evidence agenda, including Phase IIIb/IV studies, investigator-sponsored research, resistance and pharmacology strategy, and real-world and service-delivery evidence, in partnership with Clinical, Statistics and R&D.
Build and maintain effective relationships with external experts, HCPs, guideline bodies and communities, providing senior scientific expertise and facilitating medical scientific team engagement on long-acting treatment.
Ensure the scientific quality and compliance of all medical and promotional activities for the pipeline, acting as senior medical reviewer/signatory where appropriate, and proactively identifying and mitigating ABPI/PMCPA risk.
Partner with Scientific Communications to define and deliver the scientific platform, narrative and communication plan for long-acting treatment, ensuring consistency across regions.
Provide senior medical input to launch readiness, market access and commercial planning for pipeline assets, translating clinical differentiation into credible, evidence-based value messages.
Represent ViiV in senior internal governance and external scientific forums, advising leadership on the medical implications of the evolving long-acting treatment landscape and competitive environment.